Non-invasive Diagnostics Deton’s Aerosol Biopsy is a non-invasive, accurate method for obtaining genetic information from lung droplets, presenting a compelling value proposition for hospital systems and clinics seeking less risky diagnostic workflows and faster patient throughput.

Lung Health Data The technology enables access to real-time genetic data from lung-derived aerosols, creating opportunities to partner with research institutions, biopharma, and contract research organizations focusing on respiratory diseases and therapeutic development.

Clinical Adoption With a focus on treatment decisions and therapeutics development, Deton can pursue pilots with pulmonary care centers, academic medical centers, and integrated delivery networks to validate clinical utility and drive reimbursement pathways.

Strategic Partners Potential collaboration opportunities exist with large medical device and healthcare tech ecosystems seeking to expand non-invasive diagnostic portfolios, including joint development, distribution, and cloud-based data analytics integrations.

Scale Readiness Despite a small team, Deton’s current revenue range indicates momentum; sales efforts should emphasize scalable deployment, regulatory alignment, and cloud-enabled data handling to attract enterprise customers and strategic investors.